Bone loss and fracture risk associated with cancer therapy

Oncologist

Volumn 11, Issue 10, 2006, Pages 1121-1131

  Guise, Theresa A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bisphosphonates; Cancer; Chemotherapy; Fracture; Hormonal antineoplastic agents; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKYLATING AGENT; ANASTROZOLE; ANTIBIOTIC AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORHEXIDINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EXEMESTANE; GLUCOCORTICOID; IBANDRONIC ACID; IFOSFAMIDE; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; PARACETAMOL; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; STEROID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DIET RESTRICTION; DRUG ABSORPTION; DRUG DOSE REGIMEN; ESOPHAGITIS; ESOPHAGUS ULCER; EXERCISE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; JAW DISEASE; LIFESTYLE; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; VITAMIN SUPPLEMENTATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; DRUG TOXICITY; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; NEOPLASMS; OSTEOPOROSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33751203850     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-10-1121     Document Type: Review

References (76)

1. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000;18:1570-1593.
2. Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003;170:S59-S63; discussion S64.
3. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park) 2005;19:651-658.
4. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004;31:331-352.
5. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12S-17S; discussion 17S-19S.
6. King AB, Saag KG, Burge RT et al. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int 2005;16:1545-1557.
7. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003;51:364-370.
8. Schürch MA, Rizzoli R, Mermillod B et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996;11:1935-1942.
9. Kanis JA. Pathogenesis of osteoporosis and fracture. In: Kanis JA, ed. Osteoporosis. London: Blackwell Healthcare Communications Ltd., 1997:22-57.
10. Eastell R, Hannon RA, Cuzick J et al. Effect of anastrozole on bone density and bone turnover: results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study. J Bone Miner Res 2002;17(suppl 1):S165.
11. Gnant M, Hausmaninger H, Samonigg H et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Presented at the 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2002.
12. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311.
13. Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-1222.
14. Lee WY, Cho SW, Oh ES et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 2002;87:329-335.
15. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
16. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
17. Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
18. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
19. Coleman RE. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex, Tamoxifen', Alone or in Combination (ATAC) Trial. J Clin Oncol 2006;24(18 suppl). Abstract 511.
20. Howell A. Analysis of fracture risk factors from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: 5-year data. J Clin Oncol 2006;24 (18 suppl). Abstract 563.
21. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-3635. DOI: 10.1200;JCO.2005.05.4882.
22. Coleman RE, Banks LM, Girgis SI et al, on behalf of the IES Group. Skeletal effects of exemestane in the Intergroup Exemestane Study (IES). Two year bone mineral density and bone biomarker data. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2005.
23. Diamond TH, Higano CS, Smith MR et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-899.
24. Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361-2367.
25. Eriksson S, Eriksson A, Stege R et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995;57:97-99.
26. Mittan D, Lee S, Miller E et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656-3661.
27. Smith MD, Ross W, Ahern MJ. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip and wrist fractures. J Rheumatol 2001;28:2504-2508.
28. Morris CA, Cheng H, Cabral D et al. Predictors of screening and treatment of osteoporosis: a structured review of the literature. The Endocrinologist 2004:14:70-75.
29. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004. Available at http://www.surgeongeneral.gov/library/bonehealth/html. Accessed August 9, 2006.
30. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
31. Nelson HD, Helfand M, Woolf SH et al. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529-541.
32. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate Cancer v.2.2005. Available at http://www.nccn.org/ professionals/physician_gls/PDF/prostate.pdf. Accessed August 9, 2006.
33. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002;167:1952-1956.
34. Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum 2005;32:589-603.
35. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003:1-38.
36. Miller PD, Siris ES, Barrett-Connor E et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 2002;17:2222-2230.
37. Malavolta N, Mule R, Frigato M. Quantitative ultrasound assessment of bone. Aging Clin Exp Res 2004;16(suppl):23-28.
38. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
39. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183-187.
40. Maricic M, Chen Z. Bone densitometry. Clin Lab Med 2000;20:469-488.
41. Writing Group for the ISCD Position Development Conference. Technical standardization for dual-energy x-ray absorptiometry. J Clin Densitom 2004;7:27-36.
42. Haczyński J, Jakimiuk AJ. Vertebral fractures: a hidden problem of osteoporosis. Med Sci Monit 2001;7:1108-1117.
43. Ralston SH. Bone densitometry and bone biopsy. Best Pract Res Clin Rheumatol 2005;19:487-501.
44. Brufsky A, Harker G, Beck T et al. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): preliminary results of the Z-FAST trial. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2004.
45. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11:207-224.
46. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
47. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012.
48. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004;9(suppl 4):28-37.
49. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
50. Zazgornik J, Grafinger P, Biesenbach G et al. Acute renal failure and alendronate [letter]. Nephrol Dial Transplant 1997;12:2797-2798.
51. O'Sullivan TL, Akbari A, Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Ren Fail 1994;16:767-773.
52. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. The Oncologist 2005;10(suppl 1):3-7.
53. Zometa® [package insert].Zoledronic acid prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation, April 2005.
54. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [letter]. J Oral Maxillofac Surg 2003;61:1115-1117.
55. Estilo CL, Van Poznak CH, Williams T et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. J Clin Oncol 2004;22(14 suppl):747. Abstract 8088.
56. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
57. Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24(18 suppl). Abstract 8528.
58. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952.
59. Ruggiero SL, Gralow J, Marx RE et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14.
60. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
61. Sebaldt RJ, Shane LG, Pham BZ et al. Impact of non-compliance and nonpersistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis. Presented at the 26th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, WA, October 1-5, 2004.
62. Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216.
63. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-2264.
64. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(suppl):1678S-1688S.
65. Moyad MA. Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/ orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology 2002;59(suppl 1):34-40.
66. Srivastava AK, Vliet EL, Lewiecki EM et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005;21:1015-1026.
67. Tamada T, Sone T, Tomomitsu T et al. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001;19:45-51.
68. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
69. Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
70. Lipton A, Costa L, Ali S et al. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001;28(suppl 11):54-59.
71. Wehrli FW, Saha PK, Gomberg BR et al. Role of magnetic resonance for assessing structure and function of trabecular bone. Top Magn Reson Imaging 2002;13:335-355.
72. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003;15:458-463.
73. Miller PD, McClung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322.
74. Chesnut CH 3rd, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
75. Doggrell SA. Zoledronate once-yearly increases bone mineral density - implications for osteoporosis. Expert Opin Pharmacother 2002;3:1007-1009.
76. Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.